Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Panax notoginseng flower, also known as Sanqi flower, is the dried inflorescence of *Panax notoginseng* (Burk.) F.H. Chen, a traditional Chinese medicinal herb primarily cultivated in the Yunnan and Guangxi provinces of China. The flower contains a high concentration of dammarane-type saponins, including ginsenosides (such as Rb1, Rc, and Rd) and notoginsenosides, which are distinct from those found in the root. In clinical research, it is being investigated for its neuroprotective, antidepressant, and antihypertensive properties. Specifically, it is studied for the treatment of major depressive disorder and acute ischemic stroke, where it is thought to modulate neurotransmitter systems and reduce oxidative stress and neuroinflammation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on panax notoginseng flower.